Scpharmaceuticals Inc (NASDAQ:SCPH) – Equities researchers at Svb Leerink lifted their Q2 2019 EPS estimates for shares of Scpharmaceuticals in a research note issued on Wednesday, May 8th. Svb Leerink analyst A. Fadia now forecasts that the company will earn ($0.54) per share for the quarter, up from their prior forecast of ($0.58). Svb Leerink has a “Market Perform” rating on the stock. Svb Leerink also issued estimates for Scpharmaceuticals’ Q3 2019 earnings at ($0.55) EPS, Q4 2019 earnings at ($0.57) EPS and FY2019 earnings at ($2.13) EPS.
Scpharmaceuticals (NASDAQ:SCPH) last posted its quarterly earnings results on Wednesday, May 8th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.05.
Several other equities analysts have also weighed in on the stock. Zacks Investment Research raised shares of Scpharmaceuticals from a “hold” rating to a “buy” rating and set a $3.75 price objective on the stock in a research report on Thursday, May 2nd. Leerink Swann lowered shares of Scpharmaceuticals from an “outperform” rating to a “market perform” rating and cut their price objective for the company from $12.00 to $5.00 in a research report on Wednesday, January 30th. Four equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The company currently has a consensus rating of “Hold” and an average target price of $8.69.
NASDAQ SCPH opened at $3.51 on Monday. The company has a quick ratio of 13.77, a current ratio of 8.50 and a debt-to-equity ratio of 0.10. The company has a market capitalization of $65.22 million, a PE ratio of -2.21 and a beta of 1.31. Scpharmaceuticals has a 52-week low of $2.44 and a 52-week high of $15.00.
In other Scpharmaceuticals news, major shareholder Ra Capital Healthcare Fund Lp acquired 389,862 shares of the business’s stock in a transaction that occurred on Thursday, April 11th. The shares were purchased at an average price of $2.70 per share, with a total value of $1,052,627.40. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 4.80% of the stock is currently owned by company insiders.
Several large investors have recently added to or reduced their stakes in SCPH. Jacobs Levy Equity Management Inc. bought a new position in shares of Scpharmaceuticals in the first quarter valued at approximately $71,000. JPMorgan Chase & Co. raised its position in shares of Scpharmaceuticals by 1,268.6% in the third quarter. JPMorgan Chase & Co. now owns 22,664 shares of the company’s stock valued at $133,000 after purchasing an additional 21,008 shares during the period. SG Americas Securities LLC bought a new position in shares of Scpharmaceuticals in the first quarter valued at approximately $51,000. Finally, BlackRock Inc. raised its position in shares of Scpharmaceuticals by 2.0% in the fourth quarter. BlackRock Inc. now owns 358,243 shares of the company’s stock valued at $1,347,000 after purchasing an additional 7,094 shares during the period. 42.33% of the stock is currently owned by institutional investors.
scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is Furoscix that consists of proprietary subcutaneous formulation of furosemide, which is delivered through the SmartDose drug delivery system for treatment of congestion in decompensated heart failure patients outside of the acute care setting.
Featured Article: Why do companies issue convertible shares?
Receive News & Ratings for Scpharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scpharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.